Neridronic acid for reflex sympathetic dystrophy

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Oct 2025: Trial registered, NCT07210515
  2. 14 Apr 2026: Trial started, NCT07210515

The trials

NCT07210515: Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)

State
Under way
Phase
Phase 3
People
270 planned
Started
14 Apr 2026
Primary completion
Dec 2027
Arms
neridronate
Results
None posted
  1. 7 Oct 2025: Trial registered
  2. 14 Apr 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Neridronate.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.